Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (1098)	5/17/2000 10:32:00 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

I don't know much about Powderject other than they have a big deal with Glaxo for DNA vaccines as well as the chirocaine project you mentioned. Stock has been weak all this year, even for a UK biotech (recently 428p, down from a high of around 1000p late last year). Here's a piece on them from Oxford University: ox.ac.uk There's also a US company with less sophisticated needleless injection technology - Medi Ject. In the pediatric market Iomed markets something called Numby Stuff. This is lidocaine with transdermal penetration aided by electricity. Best summed up by the 10-Q: The Company introduced its local dermal anesthesia products into the market place in January 1997 and, to date, has not realized significant revenue from the sales of such products (This despite a plug on ER, where it featured in an episode a year or two back). I don't know how this differs from electroporation - Genetronics (GEB) is the micro-cap involved in this. Also needleless delivery of some sort, apparently playing in the same DNA vaccine and anesthetic markets. Peter